Latest news with #Vgenomics'

Time of India

Tear-Based Biomarker Identified for early detection of keratoconus

New Delhi: Delhi-based biotech company Vgenomics has partnered with Dr. Shroff's Charity Eye Hospital to validate and commercialize a tear-based biomarker , VSP-2224 , for the early detection of keratoconus , a progressive eye disorder affecting the cornea. VSP-2224, identified in tear fluid using Vgenomics' AI-based discovery platform RgenX-LENS, may help detect the disease earlier, before visible symptoms emerge. Clinical validation of VSP-2224 is underway. The biomarker will also be featured in OcuTear, a rapid diagnostic panel Vgenomics is developing for ocular surface diseases. Commenting on the development, Dr Anil Tiwari said, 'This partnership enables us to translate a tear-based biomarker into a clinically viable diagnostic test, with the potential to further develop it into targeted therapeutics.'